POINT BIOPHARMA GLOBAL INC (PNT) Stock Price, Quote, News and Overview
NASDAQ:PNT - Nasdaq - US7305411099 - Common Stock - Currency: USD
PNT Quote, Performance and Key Statistics
12.5
+0.02 (+0.16%)
The current stock price of PNT is 12.5 USD. In the past month the price decreased by -9.42%. In the past year, price increased by 71.47%.
PNT Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About PNT
Company Profile
POINT Biopharma Global, Inc. is a radiopharmaceutical company. The company is headquartered in Indianapolis, Indiana and currently employs 129 full-time employees. The company went IPO on 2020-07-10. The firm is engaged in building a platform for the clinical development and commercialization of radioligands that fight cancer. The firm is focused on transforming precision medicine by combining a portfolio of radiopharmaceutical assets, a seasoned management team, a pipeline, in-house manufacturing capabilities, and secured supply for rare medical isotopes like actinium-225 (Ac) and lutetium-177 (Lu). Its pipeline consists of late-stage programs in prostate cancer (PNT2002) and neuroendocrine tumors (PNT2003). Its Lu-PNT2002 is a late-stage prostate-specific membrane antigen (PSMA) targeted radioligand therapy. Its Lu-PNT2003 is a late-stage somatostatin-targeted radioligand in development for the treatment of neuroendocrine tumors. Its PNT2004 is a fibroblast activation protein-a (FAP) targeting program being developed for use in multiple tumor types.
Company Info
POINT BIOPHARMA GLOBAL INC
4850 West 78th Street
Indianapolis INDIANA US
CEO: Peter Kolchinsky
Employees: 129
Company Website: https://www.pointbiopharma.com/
Phone: 13175439957
POINT BIOPHARMA GLOBAL INC / PNT FAQ
What is the stock price of POINT BIOPHARMA GLOBAL INC today?
The current stock price of PNT is 12.5 USD. The price increased by 0.16% in the last trading session.
What is the ticker symbol for POINT BIOPHARMA GLOBAL INC stock?
The exchange symbol of POINT BIOPHARMA GLOBAL INC is PNT and it is listed on the Nasdaq exchange.
On which exchange is PNT stock listed?
PNT stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for POINT BIOPHARMA GLOBAL INC stock?
15 analysts have analysed PNT and the average price target is 15.05 USD. This implies a price increase of 20.36% is expected in the next year compared to the current price of 12.5. Check the POINT BIOPHARMA GLOBAL INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is POINT BIOPHARMA GLOBAL INC worth?
POINT BIOPHARMA GLOBAL INC (PNT) has a market capitalization of 1.33B USD. This makes PNT a Small Cap stock.
How many employees does POINT BIOPHARMA GLOBAL INC have?
POINT BIOPHARMA GLOBAL INC (PNT) currently has 129 employees.
What are the support and resistance levels for POINT BIOPHARMA GLOBAL INC (PNT) stock?
POINT BIOPHARMA GLOBAL INC (PNT) has a support level at 12.47 and a resistance level at 14.07. Check the full technical report for a detailed analysis of PNT support and resistance levels.
Is POINT BIOPHARMA GLOBAL INC (PNT) expected to grow?
The Revenue of POINT BIOPHARMA GLOBAL INC (PNT) is expected to decline by -14.35% in the next year. Check the estimates tab for more information on the PNT EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy POINT BIOPHARMA GLOBAL INC (PNT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PNT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PNT, evaluating the profitability, health, valuation and growth aspects
- POINT BIOPHARMA GLOBAL INC (PNT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- POINT BIOPHARMA GLOBAL INC (PNT) Sales and EPS estimates to see what analysts future expectations are.
- POINT BIOPHARMA GLOBAL INC (PNT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- POINT BIOPHARMA GLOBAL INC (PNT) Insider and Institutional Ownership to learn about the owners and their transactions.
- POINT BIOPHARMA GLOBAL INC (PNT) Stock Chart to make your own analysis
- POINT BIOPHARMA GLOBAL INC (PNT) Latest news and press-releases to stay up to date.
Does POINT BIOPHARMA GLOBAL INC (PNT) stock pay dividends?
PNT does not pay a dividend.
When does POINT BIOPHARMA GLOBAL INC (PNT) report earnings?
POINT BIOPHARMA GLOBAL INC (PNT) will report earnings on 2024-03-22, after the market close.
What is the Price/Earnings (PE) ratio of POINT BIOPHARMA GLOBAL INC (PNT)?
The PE ratio for POINT BIOPHARMA GLOBAL INC (PNT) is 15.06. This is based on the reported non-GAAP earnings per share of 0.83 and the current share price of 12.5 USD. Check the full fundamental report for a full analysis of the valuation metrics for PNT.
PNT Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to PNT. When comparing the yearly performance of all stocks, PNT is one of the better performing stocks in the market, outperforming 97.1% of all stocks.
PNT Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to PNT. PNT is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
PNT Financial Highlights
Over the last trailing twelve months PNT reported a non-GAAP Earnings per Share(EPS) of 0.83. The EPS increased by 195.4% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 39.62% | ||
| ROA | 20.22% | ||
| ROE | 22.77% | ||
| Debt/Equity | 0.01 |
PNT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 69% to PNT. The Buy consensus is the average rating of analysts ratings from 15 analysts.
For the next year, analysts expect an EPS growth of 9.21% and a revenue growth -14.35% for PNT